文献速递肝肾功能剂量调整抗栓抗凝管理治疗药物监测与药物基因组学

阿哌沙班抗Xa水平在慢性肾功能不全患者阿哌沙班转华法林中的应用

Utilization of apixaban anti-Xa levels in transition from apixaban to warfarin in a patient with chronic renal dysfunction.
PubMed 文献 · Am J Health Syst Pharm · 2022-01-01

本文报道一例急性加重慢性肾病并近期深静脉血栓患者从阿哌沙班转换为华法林的过程,利用显色法阿哌沙班抗Xa检测评估抗凝水平,避免了不必要的肠外抗凝。结论认为阿哌沙班抗Xa水平有助于慢性肾衰竭患者从阿哌沙班向华法林转换,并避免肠外桥接治疗。

要点

  • 阿哌沙班影响抗Xa检测和INR,使抗凝转换复杂化。
  • 肾功不全时阿哌沙班持续存在延长INR影响并维持抗凝效果。
  • 阿哌沙班抗Xa水平可辅助转换并避免不必要的肠外桥接。

核心结论

  • 利用阿哌沙班抗Xa水平有助于慢性肾衰竭患者从阿哌沙班转换为华法林,并避免肠外桥接治疗。

研究设计与样本

  • 本文为个案报道,描述一例急性加重慢性肾病并近期深静脉血栓患者从阿哌沙班转换为华法林的过程。

主要发现

  • 采用显色法阿哌沙班抗Xa检测评估抗凝水平,避免了不必要的肠外抗凝。

关键数值与推荐

  • 从阿哌沙班转换为华法林时,推荐在下一剂阿哌沙班给药时同时启用肠外抗凝剂和华法林,待INR达可接受范围后停用肠外抗凝剂。

临床怎么用

  • 在肾功能不全患者中,可考虑使用阿哌沙班抗Xa水平评估抗凝强度,以辅助阿哌沙班向华法林转换并避免不必要的肠外桥接。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The effect of apixaban on anti-factor Xa (anti-Xa) assays and international normalized ratio (INR) complicates transitions between anticoagulant agents. When switching from apixaban to warfarin, the recommendation is to begin both a parenteral anticoagulant and warfarin at the time of the next apixaban dose and to discontinue the parenteral agent when the INR is in an acceptable range. This proves challenging in renal dysfunction, as continued presence of apixaban contributes to both a prolonged effect on the INR and continued therapeutic levels of anticoagulation. SUMMARY: This case describes the transition of apixaban to warfarin in a patient with acute on chronic kidney disease and recent deep vein thrombosis, utilizing chromogenic apixaban anti-Xa assays to assess the level of anticoagulation and avoid unnecessary parenteral anticoagulation. CONCLUSION: Utilization of apixaban anti-Xa levels aided in the transition from apixaban to warfarin in a patient with chronic renal failure and avoided need for parenteral bridging therapy.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Elgersma B, Zochert S. Utilization of apixaban anti-Xa levels in transition from apixaban to warfarin in a patient with chronic renal dysfunction. Am J Health Syst Pharm. 2022. PMID: 34864841. doi:10.1093/ajhp/zxab469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。